Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
About the study
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- White Brazilian of European descent
- Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
- Eligibility to immediate-release MPH (IR-MPH) treatment
EXCLUSION CRITERIA
Exclusion Criteria:
- Contraindication for IR-MPH use
- Current stimulant treatment
- Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
- Current or past history of psychosis
- Estimated intelligence quotient score lower than 70
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Attention Deficit Disorder With Hyperactivity
Age (in years)
18+
Phase
Phase 4
Participants needed
600
Est. Completion Date
Dec 31, 2032
Treatment type
Interventional
Sponsor
Hospital de Clinicas de Porto Alegre
ClinicalTrials.gov identifier
NCT02951754
Study number
100358
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?